Jiang Zhu's Biography

• Home
• |
• Register
• |
• Submissions
  • Submission Guidelines
  • Submissions
• |
• Agenda
• |
• Exhibition
• |
• Venue
• |
• Media
• |

Antibody Discovery and Vaccine Design – The Next Generation

Tuesday, 25 February 2014 at 16:45

Add to Calendar ▼2014-02-25 16:45:002014-02-25 17:45:00Europe/LondonAntibody Discovery and Vaccine Design – The Next GenerationNext Generation Sequencing: Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

By combining next-generation sequencing and bioinformatics, antibodyomics has emerged as a powerful technology for the quantitative analysis of antibody repertoire and response and is poised to revolutionize antibody discovery and vaccine design. This trend was evidenced by recent breakthroughs in the analysis of broadly neutralizing HIV-1 antibodies. Starting from millions of antibody sequences obtained from deep sequencing, one can identify the entire somatic population for a known broadly neutralizing antibody isolated from the same sample, delineate the B-cell ontogeny of broadly neutralizing antibody lineages, de novo identify broadly neutralizing antibodies from a donor sample with uncharacterized antibody status, and track antigen-specific temporal antibody response in natural infections and vaccine clinical trials. It is foreseeable that this technology will significantly accelerate antibody discovery and vaccine design for pathogens such as HIV-1, influenza, respiratory syncytial virus, hepatitis C virus and human cytomegalovirus. The application of antibodyomics to autoimmune diseases and tumors/cancers is also being explored.